milrinone has been researched along with natriuretic peptide, brain in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (78.57) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Herring, N; Paterson, DJ; Zaman, JA | 1 |
| Poole-Wilson, PA | 1 |
| Young, JB | 1 |
| Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM | 1 |
| Aranda, JM; Hill, JA; Hsu, K; Pauly, DF; Schofield, R | 1 |
| Liu, HX; Xu, XW; Yang, W; Zeng, GY; Zhao, ZY | 1 |
| Abraham, WT; Akers, WS; Gurram, NR; Lewis, DA | 1 |
| Sharma, M; Teerlink, JR | 1 |
| Alexander, KS; Fink, JM; Honisko, ME; Mauro, VF; Militello, MA | 1 |
| Saltzberg, MT | 1 |
| Jorde, UP; Smull, DL | 1 |
| Abraham, WT; Adams, KF; Berkowitz, RL; Cheng, ML; Costanzo, MR; Fonarow, GC; LeJemtel, TH; Wynne, J | 1 |
| Dec, GW | 1 |
| Mehra, MR | 1 |
| Arnold, LM; Carroll, NV; Crouch, MA; Oinonen, MJ | 1 |
| Kurien, S; Miller, WL; Warfield, KT; Wood, CM | 1 |
| Brackbill, ML; Dhavle, AA; Schuller-Williams, RV; Stam, MD | 1 |
| Blais, DM | 1 |
| Adams, S; Mather, PJ; Rubin, S; Saltzman, HE; Sharma, K; Whellan, DJ | 1 |
| Tobias, JD | 1 |
| Askovich, B; Berry, JG; Cowley, CG; Hawkins, JA; Shaddy, RE | 1 |
| Heywood, JT; Khan, TA | 1 |
| Coons, JC; McGraw, M; Murali, S | 1 |
| Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C | 1 |
| Adamczyk, A; Azer, J; Bissell, MB; Hua, R; McBoyle, S; Robbins, C; Rose, RA; Springer, J | 1 |
| Allan, CK; Costello, JM; Dionne, RE; Dunbar-Masterson, C; Gauvreau, K; Laussen, PC; Mayer, JE; McGowan, FX; Newburger, JW; Salvin, JW; Wessel, DL | 1 |
| Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S | 1 |
| Knudsen, PK; Kristoffersen, AW; Møller, T | 1 |
10 review(s) available for milrinone and natriuretic peptide, brain
| Article | Year |
|---|---|
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents | 2001 |
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents | 2003 |
A rational approach for the treatment of acute heart failure: current strategies and future options.
Topics: Acute Disease; Adenosine; Cardiotonic Agents; Catheterization, Swan-Ganz; Dobutamine; Drug Therapy; Endothelins; Forecasting; Heart Failure; Humans; Milrinone; Natriuretic Peptide, Brain; Vasopressins | 2004 |
Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
Topics: Cardiotonic Agents; Decision Trees; Emergency Treatment; Heart Failure; Humans; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Vasodilator Agents | 2004 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
Nesiritide compared with milrinone for cardiac surgery.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiac Output, Low; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Phosphodiesterase Inhibitors; Risk Assessment; Thoracic Surgery | 2007 |
Renal dysfunction in heart failure patients: what is the evidence?
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Catheterization; Cardiac Pacing, Artificial; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Milrinone; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Renal Insufficiency, Chronic; Treatment Outcome; Ultrafiltration | 2007 |
The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Topics: Acute Disease; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Kidney; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitrates; Sympathomimetics; Vasodilator Agents | 2007 |
Pharmacotherapy for acute heart failure syndromes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Dobutamine; Heart Failure; Humans; Milrinone; Morphine; Natriuretic Peptide, Brain; Nitroglycerin; Nitroprusside; Practice Guidelines as Topic; Vasodilator Agents | 2011 |
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Topics: Aged; Disease Progression; Dobutamine; Dopamine; Epinephrine; Female; Hemodynamics; Humans; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Network Meta-Analysis; Norepinephrine; Patient Safety; Recombinant Proteins; Shock, Cardiogenic; Simendan; Treatment Outcome | 2020 |
2 trial(s) available for milrinone and natriuretic peptide, brain
| Article | Year |
|---|---|
Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients.
Topics: Adult; Aged; Aged, 80 and over; Cardiac Output, Low; Cardiotonic Agents; Coronary Artery Bypass; Female; Hospitals, Voluntary; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Perioperative Care | 2007 |
Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Cardiotonic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Heart Failure; Humans; Infant; Infusions, Intravenous; Length of Stay; Male; Milrinone; Natriuretic Peptide, Brain; Postoperative Care; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Ventricular Function, Left | 2014 |
16 other study(ies) available for milrinone and natriuretic peptide, brain
| Article | Year |
|---|---|
Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway.
Topics: Acetylcholine; Animals; Atrial Natriuretic Factor; Bradycardia; Calcium Channel Blockers; Carbachol; Cardiotonic Agents; Cyclic GMP; Enzyme Inhibitors; Female; Gene Expression; Guanylate Cyclase; Guinea Pigs; Heart Rate; Isoquinolines; Milrinone; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Nitric Oxide; omega-Conotoxins; Phosphodiesterase Inhibitors; Polysaccharides; Receptors, Atrial Natriuretic Factor; RNA, Messenger; Sulfonamides; Synaptic Transmission; Tritium; Vagus Nerve | 2001 |
Treatment of acute heart failure: out with the old, in with the new.
Topics: Acute Disease; Atrial Natriuretic Factor; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Natriuretic Peptide, Brain; Nitroglycerin; Treatment Failure | 2002 |
Sustained use of nesiritide to aid in bridging to heart transplant.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Diuretics; Dobutamine; Dopamine; Drug Therapy, Combination; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Preoperative Care; Time Factors; Treatment Outcome; Waiting Lists | 2003 |
[Effects of recombinant human brain natriuretic peptide and milrinone on cardiac hemodynamics and renal function in anesthetized dog].
Topics: Anesthesia; Animals; Cardiotonic Agents; Dogs; Drug Interactions; Female; Heart; Hemodynamics; Kidney; Male; Milrinone; Natriuretic Peptide, Brain; Recombinant Proteins; Sodium; Urine | 2002 |
Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Topics: Acute Disease; Aged; Endpoint Determination; Heart Failure; Hemodynamics; Humans; Length of Stay; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Patient Readmission; Retrospective Studies; Treatment Outcome; Vasodilator Agents | 2003 |
Compatibility of argatroban with selected cardiovascular agents.
Topics: Amiodarone; Anticoagulants; Arginine; Cardiovascular Agents; Drug Interactions; Drug Therapy, Combination; Fenoldopam; Furosemide; Humans; Infusions, Parenteral; Lidocaine; Milrinone; Natriuretic Peptide, Brain; Nitroglycerin; Nitroprusside; Pipecolic Acids; Sulfonamides; Vasopressins | 2004 |
Concomitant use of nesiritide and milrinone in decompensated congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiotonic Agents; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypotension; Male; Medical Records; Middle Aged; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Prospective Studies; Pulmonary Wedge Pressure | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Hospital Mortality; Humans; Infusions, Intravenous; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Nitroglycerin; Retrospective Studies | 2005 |
Acute decompensated heart failure: the shrinking role of inotropic therapy.
Topics: Acute Disease; Cardiovascular Agents; Dobutamine; Heart Failure; Humans; Milrinone; Natriuretic Peptide, Brain; Nitroglycerin; Treatment Outcome | 2005 |
Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Health Care Costs; Heart Failure; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Odds Ratio; Patient Readmission; Regression Analysis; Retrospective Studies; Treatment Outcome | 2006 |
Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Topics: Aged; Cardiotonic Agents; Creatinine; Diuretics; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Kidney; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Survival Rate; Urine | 2006 |
Hemolytic-uremic syndrome and myocardial dysfunction in a 9-month-old boy.
Topics: Anemia; Anti-Bacterial Agents; Cardiomyopathies; Cardiotonic Agents; Dopamine; Electrocardiography; Hemolytic-Uremic Syndrome; Humans; Infant; Intubation, Intratracheal; Male; Meropenem; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Oliguria; Peritoneal Dialysis; Renal Dialysis; Renal Insufficiency; Respiration, Artificial; Thienamycins; Vancomycin | 2007 |
Prognostic value of B-type natriuretic peptide in surgical palliation of children with single-ventricle congenital heart disease.
Topics: Cardiotonic Agents; Dobutamine; Female; Fontan Procedure; Heart Bypass, Right; Heart Defects, Congenital; Heart Ventricles; Humans; Infant; Length of Stay; Male; Milrinone; Multivariate Analysis; Natriuretic Peptide, Brain; Palliative Care; Postoperative Period; Prognosis; Prospective Studies | 2008 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Atrial Function; Atrial Natriuretic Factor; Electric Conductivity; Guanylate Cyclase; Heart Atria; Heart Rate; In Vitro Techniques; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Milrinone; Myocytes, Cardiac; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Patch-Clamp Techniques; Peptide Fragments; Phosphodiesterase 3 Inhibitors; Receptors, Atrial Natriuretic Factor; Sinoatrial Node; Stimulation, Chemical; Tetrahydroisoquinolines | 2012 |
SARS-CoV-2 infection in an infant with severe dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; COVID-19; Diarrhea; Diuretics; Echocardiography; Enterovirus Infections; Female; Fever; Heart Rate; Heart Transplantation; Humans; Infant; Milrinone; Myocarditis; Natriuretic Peptide, Brain; Peptide Fragments; SARS-CoV-2; Severity of Illness Index; Tachycardia; Tachypnea; Troponin T; Ventricular Dysfunction, Left; Vomiting; Waiting Lists; Water-Electrolyte Balance | 2021 |